Next Article in Journal
The Coming of Age of Biosimilars: A Personal Perspective
Previous Article in Journal
High Altitude Cerebral Edema: Improving Treatment Options
 
 
Review
Peer-Review Record

Therapeutic Role of Antimicrobial Peptides in Diabetes Mellitus

Biologics 2022, 2(1), 92-106; https://doi.org/10.3390/biologics2010008
by Julia Depta 1, Paulina Małkowska 1,2, Monika Wysokińska 1, Karolina Todorska 1, Olga Sierawska 1,2,*, Rafał Hrynkiewicz 1, Dominika Bębnowska 1 and Paulina Niedźwiedzka-Rystwej 1
Reviewer 1: Anonymous
Reviewer 2: Anonymous
Biologics 2022, 2(1), 92-106; https://doi.org/10.3390/biologics2010008
Submission received: 13 January 2022 / Revised: 7 March 2022 / Accepted: 14 March 2022 / Published: 18 March 2022
(This article belongs to the Special Issue Antimicrobial Peptides for Therapeutic Applications)

Round 1

Reviewer 1 Report

The manuscript "Therapeutic role of Antimicrobial Peptides in Diabetes Mellitus " requires significant changes

Abstract.                                                                                                             ABBREVIATIONS: first, write the whole text, and in parentheses the abbreviation.

Line 12: antimicrobial peptides (AMPs)

Line 13: CRAM, cAMP, and BDM

Line 14: LL-37, and LL-37 and HNP1, HNP2, HNP3

Line 16: HBD2

Line 18:  M13

Correct abbreviation in the manuscript

Keywords: add: diabetic foot; tuberculosis

Introduction

Line 32-34: Please delete this sentence „Occurrence of hyperglycemia is one of its characteristics, which can be caused by incorrect insulin expression, insulin malfunction activity, or both. Chronic untreated diabetes affects eyes, kidneys, nerves and increases the chances of developing cardiovascular disease“. Please change this sentence to the following: “Diabetes mellitus is a heterogeneous metabolic disorder characterized by the presence of hyperglycemia due to impairment of insulin secretion, defective insulin action or both.“

Please replace this sentence: „The chronic hyperglycemia of diabetes is associated with relatively specific long-term microvascular complications affecting the eyes, kidneys, and nerves and an increased risk for cardiovascular disease (CVD), “according to ref. (4) Diabetes Canada Clinical Practice Guidelines Expert Committee; Punthakee, Z.; Goldenberg, R.; Katz, P. 516 Definition, Classification and Diagnosis of Diabetes, Prediabetes and Metabolic Syndrome. Can. J. Diabetes 2018, 42 Suppl 517 1, S10–S15, doi:10.1016/j.jcjd.2017.10.003.

Line 51: to add. Methods: Specify the inclusion and exclusion criteria for the review. Specify the information sources (e.g., databases, registers)   Specify the methods used to assess the risk of bias in the included studies. Specify the methods used to present and synthesize results.

  1. AMPs characteristics

Line 58-63 historical information on AMP is found in earlier reports (9-11), so the reviewer recommends omitting it.

Line 90 ref. (32) and line 111 ref 40; same ref.

2.1. AMPs modifications

Line 118 ref. (42) and line 122 ref (43); same ref. Several duplicate references are under different numbers, and the authors need to check.

  1. Role of AMPs in type I diabetes

Line 159-160: Please explain this sentenceThe lack of properly functioning β-159 cells leads to a decrease in the amount of produced insulin, which disrupts the proper functioning of the digestive system.”

Line 169: The possible effect of CRAMP on autoimmune diabetes was investigated in 2015 (ref. ?)

  1. Conclusions

Conclusions should be significantly shortened. Write what is essential in a few sentences and without references.

References

Line 534: ref. 12:  why capital letters

Line 544: ref. 17: why capital letters

Line 534-545: references older than 60 years

Line 607-608: Please correct this ref. Yasin, B.; Pang, M.; Turner, J.S.; Cho, Y.; Dinh, N.N.; Waring, A.J.; Lehrer, R.I.; Wagar, E.A. Evaluation of the 607 Inactivation of Infectious Herpes Simplex Virus by Host-Defense Peptides. Eur. J. Clin. Microbiol. Infect. Dis. Off. Publ. 608 Eur. Soc. Clin. Microbiol. 2000, 19, 187–194, doi:10.1007/s100960050457.

Line 563: ref. 25; line 574 ref.30 same refs.

Several duplicate references are under different numbers, and the authors need to check.

Authors are advised to submit the manuscript for English editing.

Author Response

Please see the attachment.

Author Response File: Author Response.docx

Reviewer 2 Report

The article by Depta et al. discusses the possible involvement of antimicrobial peptides (AMPs) with the evolution of the metabolic disease diabetes mellitus (DM). The therapeutic potential of various AMPs in the treatment of DM is discussed. The subject is very relevant today. The text is interesting, but an extensive English review is recommended. In table 1, the information presented in origin and effect fields is not uniform. The information needs to be objective and succinct. Duplicate references were also detected in the reference list:

  1. Huang, Y.; Huang, J.; Chen, Y. Alpha-Helical Cationic Antimicrobial Peptides: Relationships of Structure and Function. Protein Cell 2010, 1, 143–152, doi:10.1007/s13238-010-0004-3.
  2. Huang, Y.; Huang, J.; Chen, Y. Alpha-Helical Cationic Antimicrobial Peptides: Relationships of Structure and Function. Protein Cell 2010, 1, 143–152, doi:10.1007/s13238-010-0004-3.
  3. Wang, G. Post-Translational Modifications of Natural Antimicrobial Peptides and Strategies for Peptide Engineering. Curr. Biotechnol. 2012, 1, 72–79, doi:10.2174/2211550111201010072.
  4. Wang, G. Post-Translational Modifications of Natural Antimicrobial Peptides and Strategies for Peptide Engineering. Curr. Biotechnol. 2012, 1, 72–79, doi:10.2174/2211550111201010072.

Author Response

Please see the attachment.

Author Response File: Author Response.docx

Round 2

Reviewer 1 Report

The authors made the required corrections.

Back to TopTop